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AORTIC CARBOXYPEPTIDASE-LIKE PROTEIN SIGNALING ON STIFF 
COLLAGEN MATRICES AND CONDITIONAL DELETION IN MICE 
 
JOSEPH M. PHALEN 
 
 
ABSTRACT  
Idiopathic pulmonary fibrosis (IPF) is a disease in which the accumulation of 
excess extracellular matrix proteins including collagen causes thickening and scarring of 
the lung tissue leading to a decline in lung function. There are currently no effective 
treatments for this disease. In addition to collagen, IPF lungs contain α-smooth muscle 
actin (SMA) expressing myofibroblasts, which leads to increased tissue stiffness. Work 
in this laboratory lead to the discovery of aortic carboxypeptidase-like protein (ACLP), 
which is upregulated in the lungs of IPF patients. Previous work in this laboratory also 
demonstrated that ACLP induces SMA expression and collagen deposition. Additionally, 
ACLP knockout mice were protected against bleomycin-induced fibrosis. Matrix 
stiffening was also shown to increase the effect of ACLP and create a fibrotic feed 
forward mechanism through mechanical signaling. These findings led to the hypothesis 
that the presence of ACLP and collagen on a stiff matrix would increase expression of 
myofibroblast markers. The goal of this research was to further understand the 
relationship between ACLP, collagen, and mechanical signaling. An additional goal of 
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this work was to generate a novel mouse system in which ACLP can be conditionally 
deleted through cre-mediated recombination. Using primary lung fibroblasts plated on a 
collagen and ACLP coated matrices, ACLP increased the expression of myofibroblast 
markers and potentiated the effects of exogenous transforming growth factor β (TGFβ). 
Experiments using this central collagen binding discoidin domain of ACLP did not detect 
changes in TGFβ signaling. To develop a conditional ACLP deletion mouse model, 
optimized genotyping procedures we developed to detect recombination in response to 
cre-mediated recombination. Taken together these studies identified a relationship 
between ACLP and mechanical signaling, which can be targeted for treatment of IPF. In 
addition, the new mouse model will enable future studies to better define the function of 
ACLP in fibrotic disease.    
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CHAPTER 1 
INTRODUCTION 
 
FIBROTIC DISEASE 
 
 Fibrosis is often defined as the thickening or scarring of connective tissue (Wynn, 
2007). It is the result of dysregulated or uncontrolled wound healing, which leads to the 
accumulation of extracellular matrix (ECM) components including collagen (Wynn, 
2007). This process is believed to be initiated by inflammatory responses to a variety of 
stimuli, which ultimately lead to organ malfunction. Fibrosis in any organ is often fatal, 
such as in end stage liver disease, kidney disease, idiopathic pulmonary fibrosis, and 
heart failure (Wynn & Ramalingam, 2012). Fibrosis is a significant cause of morbidity 
and mortality, and currently there are no effective therapies to prevent its progression 
(Wynn & Ramalingam, 2012).  
Wound healing is a physiologic process that repairs an injury and reestablishes 
normal tissue function. Following injury and an initial inflammatory response, the wound 
healing response includes increased cell proliferation, migration, and ECM deposition 
(Darby & Hewitson, 2007). In normal wound healing these processes are followed by 
resolution and remodeling (Darby & Hewitson, 2007). The resolution and remodeling 
phases are significant for restoring function because during these phases the connective 
tissue that was deposited is remodeled to match the normal architecture of the tissue 
(Shaw & Martin, 2009). Additionally, the inflammatory response is stopped and the cells 
that secrete ECM material, myofibroblasts, undergo apoptosis (Shaw & Martin, 2009). 
When chronic injury occurs, wound healing processes become uncoordinated (Darby & 
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Hewitson, 2007). As a consequence of this disruption, excess matrix is often produced in 
the form of a scar (Darby & Hewitson, 2007).  
  One example of fibrotic disease that currently lacks a treatment is idiopathic 
pulmonary fibrosis (IPF). Because there are currently no effective therapies for this 
disease, median survival is from 2.5 to 3.5 years after diagnosis (Ley et al., 2011). IPF is 
the most prevalent form of idiopathic interstitial pneumonia (Ley et al., 2011). The cause 
of this fibrosis is unknown, which is why it is referred to as idiopathic. Patients with IPF 
are speculated to have repeated injuries to the alveolar epithelial cells, which results in 
the continuous cycle of unsuccessful wound healing and tissue scarring (Kim et al, 2015). 
Patients with IPF display dyspnea and a slow decline in lung function as fibrosis 
progresses (Ley et al., 2011).  
  As described above, there are currently no effective therapies for IPF; however 
several strategies and targets have been tried. N-acetylcysteine acts by restoring 
glutathione, which is an anti-oxidant, and was suggested for use to treat IPF because IPF 
patients have an imbalance in oxidation and are often low in glutathione (Meyer et al., 
1994). However, N-acetylcysteine was ineffective when compared to a placebo (Covvey 
& Mancl, 2014). Anticoagulation therapies were also determined ineffective through 
patient trials (Tomassetti et al., 2013). A drug that may hold promise is pirfenidone, 
which is an antifibrotic and anti-inflammatory agent developed specifically for IPF (Potts 
& Yogaratnam, 2013). This drug was approved in Japan and Europe, but not in the 
United States (Covvey & Mancl, 2014). However, recent trials have shown positive 
results and the application for approval of pirfenidone has been resubmitted this past year 
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with promise of being the first recommended treatment for IPF (Covvey & Mancl, 2014). 
Lastly, nintedanib, a tyrosine kinase inhibitor, has shown promising results for IPF 
treatment in clinical trials (Wollin et al., 2015). Despite these limited successes, new 
targets and therapies for IPF and other fibrotic diseases are needed. 
  
FIBROTIC MECHANISMS  
Fibroblast to Myofibroblast Differentiation  
 Fibroblasts are located within the connective tissue throughout the body (Kendall 
& Feghali-Bostwick, 2014). They produce structural ECM proteins such as collagen, 
elastin and adhesive proteins including fibronectin and laminin (Kendall & Feghali-
Bostwick, 2014). Through these functions, fibroblasts maintain the ECM (Kendall & 
Feghali-Bostwick, 2014). In wound healing and fibrosis fibroblasts differentiate into 
myofibroblasts, which are cells with increased contractile and ECM production abilities 
(Darby & Hewitson, 2007).  
Myofibroblasts play a key role in wound healing as they are involved in wound 
contraction and matrix deposition (Sarrazy et al., 2011). Myofibroblasts are proliferative 
cells that express α-smooth muscle actin (SMA), which provides them with their 
contractile ability (Hinz, 2007). Along with resident fibroblasts, there are other possible 
sources of myofibroblasts such as epithelial cells that go through epithelial to 
mesenchymal transformation (EMT) and bone marrow derived fibrocytes (Sarrazy et al., 
2011). During the fibrotic process myofibroblasts remain activated, which leads to an 
excess accumulation of collagen (Wilson & Wynn, 2009).  
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Transforming Growth Factor β (TGFβ)  
 Transforming growth factor β (TGFβ) is a cytokine that is found in tissues 
throughout the body (Branton & Kopp, 1999). TGFβ is a multifunctional regulator and 
controls both the expression of ECM proteins and inhibits their degradation (Branton & 
Kopp, 1999). These actions make TGFβ a key player in tissue repair as it is released by 
many parenchymal and infiltrating cells during injury (Branton & Kopp, 1999). 
Furthermore, TGFβ signaling is important in fibrotic disease progression (Zhang et al., 
1996).   
 
Activation and Signaling  
 TGFβ is produced as a latent precursor and associates with latency associated 
latent peptide (LAP) (Saharinen et al., 1996). TGFβ binding proteins (LTBPs) interact 
with LAP and this complex prevents TGFβ from binding to its receptors (Saharinen et al., 
1996). Proteolytic cleavage by matrix metalloproteinases (Yu & Stamenkovic, 2000), 
interaction with thrombospondin (Tsp) (Schultz-Cherry & Murphy-Ullrich, 1993) or αvβ6 
integrin (Munger et al., 1999) activate TGFβ from the latent complex. This activation 
occurs after the latent precursor is secreted into the ECM (Saharinen et al., 1996).  
 Active TGFβ binds to serine/threonine kinase receptors known as TGFβ type II 
receptors, which then cross phosphorylate TGFβ receptor I (Wrana et al., 1994). This 
cross phosphorylation leads to the activation of TGFβ receptor I. In addition to the type II 
receptor, TGFβ also binds to an accessory receptor known as endoglin (Lebrin et al., 
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2004). Lastly, betaglycan is another known receptor for TGFβ and it shares homology 
with endoglin. Betaglycan binds all TGFβ isoforms while endoglin binds more 
selectively to TGFβ-1 and TGFβ-3 isoforms (Lux et al., 1999). When bound to TGFβ, 
these receptors signal through Smad dependent and independent pathways (Derynck & 
Zhang, 2003).  
The activated TGFβ receptor I, phosphorylates Smad2 and Smad3, which bind to 
Smad4 and this complex translocates into the nucleus where it activates transcription of 
several profibrotic genes (Feng & Derynck, 2005). Smad1/5/8 are also involved in 
signaling, however, these Smads are involved in signaling from bone morphogenetic 
protein (BMP) receptors (Roberts, 1999). Although Smad1 is primarily associated with 
BMP receptors, it has also been shown to be activated by a TGFβ ligand (Lechleider et 
al., 1996). For example, human breast cancer cells treated with TGFβ showed Smad1 
phosphorylation (Liu et al., 1998). Furthermore, Smad1 phosphorylation is correlated 
with increased collagen in scleroderma fibroblasts (Morris et al., 2011). TGFβ also 
signals through Smad independent pathways. For example, TGFβ activates Erk, JNK and 
p38 MAPK kinase pathways (Derynck & Zhang, 2003). An additional example of this 
includes the induction of collagen expression in mesangial cells through TGFβ activated 
kinase 1 (TAK1) (Ono et al., 2003). Modulation of TAK1 expression through deletion in 
mice lowered interstitial myofibroblast accumulation, collagen deposition and expression 
of pro-fibrotic molecules (Ma et al., 2011).  
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TGFβ AND LUNG FIBROSIS 
 Much of what is known about fibrotic mechanisms and TGFβ in vivo has come 
from animal models including the use of bleomycin, which is a drug that was originally 
isolated from Streptomyces verticillatus (Moore & Hogaboam, 2008). Bleomycin is 
effective against squamous cell carcinomas, however, it also is toxic to the lungs at 
higher doses (Adamson, 1976). Bleomycin causes pulmonary fibrosis in mice, rats, 
primates, hamsters, guinea pigs, rabbits and dogs and the bleomycin induced fibrosis 
murine model is currently one of the best defined models for pulmonary fibrosis (Moore 
& Hogaboam, 2008). The levels of TGFβ increase in lungs of mice that have bleomycin 
induced fibrosis (Zhang et al., 1996). TGFβ increases expression of SMA in fibroblasts 
through Smad activation (Zhang et al., 1996). Furthermore, TGFβ signaling increases 
collagen deposition (Serini et al., 1998). The importance of TGFβ in fibrosis was 
demonstrated by studies examining Smad3 knockout in mice. Compared to control mice, 
Smad3 knockdown mice exhibit less fibrosis when treated with bleomycin (Zhao et al., 
2002). Smad3 deficient mice also contain lowered type 1 collagen mRNA expression and 
decreased hydroxyproline in the lungs when compared to control mice (Zhao et al., 
2002). Furthermore, Smad3 overexpression is sufficient to increase expression of SMA in 
fibroblasts (Liu et al., 2010). Together, these studies demonstrate the importance of TGFβ 
in fibrosis; however, the targeting of TGFβ has not resulted in a successful therapy 
without unwanted or harmful side effects (Datta et al., 2011).  
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MECHANICAL SIGNALING  
 In addition to TGFβ signaling, the mechanical environment in fibrotic tissue also 
contributes significantly to myofibroblast differentiation and fibrotic disease progression. 
For example, excess deposition of collagen and ECM components in the fibrotic tissue 
results in a 6 fold greater tissue stiffness than in the normal lung parenchyma (Liu et al., 
2010). This increased stiffness acts as a feed forward signaling mechanism, causing the 
differentiation of fibroblasts to myofibroblasts through increases in latent TGFβ 
activation, SMA expression, collagen accumulation, myofibroblast proliferation and 
tissue contraction (Marinković et al., 2013).  
 Myofibroblasts isolated from fibrotic lung tissue contain reduced levels of and 
reduced responsiveness to prostaglandin PGE2, which is an inhibitor of fibroblast 
proliferation and collagen synthesis (Keerthisingam et al., 2001). Additionally, these 
myofibroblasts express a reduced amount of cyclooxygenase-2 (COX-2), which is the 
rate limiting enzyme in prostanoid synthesis (Keerthisingam et al., 2001). Matrix stiffness 
has been demonstrated to regulate COX-2 expression (Liu et al., 2010). Furthermore, 
physiologically soft matrices inhibit proliferative and contractile properties of the 
myofibroblasts (Marinković et al., 2013). Transferring myofibroblasts to mechanical 
environments that match the stiffness of normal lung tissue results in reduced 
proliferation and procollagen I synthesis (Liu et al., 2010).  
 The Rho/Rho kinase (Rho/ROCK) pathway is involved in a mechanotransduction 
pathway that controls myofibroblast differentiation and survival (Zhou et al., 2013). This 
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pathway contains serine/threonine kinases that are activated by Rho GTPases. Rho 
GTPases are comparable to regulatory GTPases, which are molecular switches that are 
activated when GTP is bound and inactive when GDP is bound (Aelst & D’Souza-
Schorey, 1997). The Rho GTPase in cells provides a function of responding to matrix 
stiffness through ROCK (Provenzano & Keely, 2011). Increased matrix stiffness 
activates RhoA and ultimately increases SMA expression and stress fiber formation 
(Huang et al., 2012). The inhibition of RhoA blocks matrix stiffening induced SMA 
expression (Liu et al., 2010). Additionally, the importance of this pathway was 
demonstrated by the inhibition of fibroblast proliferation and differentiation in bleomycin 
treated mice with the ROCK inhibitor Y-27632 (Zhou et al., 2013). This inhibition 
induced apoptosis which was specific to myofibroblasts and not normal cells (Zhou et al., 
2013). With a further understanding of the ROCK pathway, therapies can be created that 
target key players in the pathway to slow the progression or stop fibrosis.  
 
AORTIC CARBOXYPEPTIDASE-LIKE PROTEIN 
Overview  
 Aortic carboxypeptidase-like protein (ACLP) is a large secreted protein originally 
cloned from human aortic vascular smooth muscle cells (Layne et al., 1998)(reviewed in 
Tumelty & Layne, 2013). A related cDNA termed adipocyte enhancer binding protein I 
(AEBP-1), was described as a smaller variant of ACLP and most now believe it is a 
cloning artifact (reviewed in Tumelty & Layne, 2013). ACLP is a secreted protein which 
associates with the ECM and contains an N-terminal signal sequence, a lysine, proline 
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and glutamic acid rich domain, a discoidin domain, and a catalytically inactive 
metallocarboxypeptidase domain (Fricker et al., 1998). 
 
ACLP Domain Structure 
 ACLP contains an inactive 500 amino acid metallocarboxypeptidase domain and 
has similarity to carboxypeptidase E (Fricker et al., 1998). The inactivity is due to the 
divergence of key amino acids within the catalytic domain (Fricker et al., 1998). For 
example, carboxypeptidases bind zinc through a histidine residue, however, in ACLP this 
histidine residue is replaced by asparagine (Layne et al., 1998). Furthermore, tyrosine and 
glutamic acid residues are important in carboxypeptidases because they are carry out the 
catalytic activity, but in ACLP these residues are replaced by asparagine and tyrosine 
respectively (Layne et al., 1998). The exact role of this domain in ACLP has not yet been 
elucidated.  
 ACLP also contains a central discoidin-like domain (Layne et al., 1998). This 
domain was originally identified in proteins in the slime mold Dictyostelium discoideum 
and were described as lectins or carbohydrate binding proteins (Poole et al., 1981). This 
discoidin domain was later found in coagulation proteins V and VIII, milk fat globule 
proteins, neuropilins, neurexin IV and the discoidin domain receptor (DDR) proteins 
(Dyka et al., 2008). DDRs bind to and are activated by fibrillar collagens (Vogel et al., 
1997) and these tyrosine kinase receptors control collagen deposition (Agarwal et al., 
2007). Additionally, DDR1 expression is required for the progression of lung 
inflammation and fibrosis (Avivi-Green et al., 2006). Work from this laboratory 
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determined that the ACLP discoidin domain causes myofibroblasts to contract collagen 
gels and enhances cell spreading on collagen matrices (Schissel et al., 2009).  
 At the N-terminus of ACLP there is a conserved signal peptide that targets the 
protein to the secretory pathway (Tumelty & Layne, 2013). The N-terminus also contains 
a region that is rich in lysine, proline and glutamic acid (Tumelty & Layne, 2013). ACLP 
is glycosylated at a minimum of four consensus N-linked sites while it moves through the 
secretory pathway (Tumelty & Layne, 2013).   
 
ACLP and Fibrosis 
 ACLP is secreted by fibroblasts, myofibroblasts, and smooth muscle cells (Layne 
et al., 1998). ACLP expression is increased in human fibrotic lung tissue and it is also 
increased in mice with bleomycin induced fibrosis (Schissel et al., 2009). In response to a 
fibrotic injury, ACLP-deficient mice contained fewer myofibroblasts and lower collagen 
levels (Schissel et al., 2009). Our laboratory’s recent work demonstrated that during the 
fibroblast to myofibroblast transition, ACLP expression preceded SMA and collagen 
expression (Tumelty et al., 2014). Moreover, recombinant ACLP increased SMA and 
collagen expression in human and mouse fibroblasts and the knockdown of ACLP 
reduced fibroblast to myofibroblast differentiation (Tumelty et al., 2014). ACLP also 
enhanced TGFβ signaling resulting in increased SMA. Lastly, ACLP stimulated TGFβ 
independent pathways leading to collagen expression but these pathways are poorly 
understood (Tumelty et al., 2014). ACLP’s importance in the progression of IPF has been 
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demonstrated in this laboratory and it is possible that ACLP can be a target for IPF 
treatment.   
 
SUMMARY 
 IPF is a fatal disease that results in the scarring of lung tissue due to the fibrotic 
process. This process involves myofibroblast differentiation, which results in collagen 
deposition and SMA expression. TGFβ signaling plays a major role in the differentiation 
of myofibroblasts and recent work in this laboratory has also shown that ACLP also 
induces this transition. In addition to these signaling pathways, mechanical signaling has 
an influence on the fibrotic process. The effects of this pathway on ACLP action need 
further investigation in order to develop a better understanding of the progression of 
fibrosis.  
 
The goals of this research were to investigate the effects of ACLP on stiff 
matrices. An additional goal was to develop assays to detect cre-recombination in a 
novel conditional ACLP mouse model. In order to gain a better understanding of the 
effects of matrix stiffness and mechanical signaling on ACLP action it was hypothesized 
that the combination of ACLP and collagen I on a stiff matrix would increase expression 
of myofibroblast markers.  
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CHAPTER 2 
METHODS 
Cell culture 
IMR90 human fetal lung fibroblasts (ATCC) were cultured in Dulbecco’s 
Modification of Eagle’s Medium (DMEM) (Corning) containing 10% fetal bovine serum 
(FBS, Hyclone) and 1% penicillin/streptomycin (Corning). The cells were incubated at 
37°C and 5% CO2. In certain experiments, cells were starved in DMEM containing 0.5% 
FBS and 1% penicillin/streptomycin.  
 Primary lung fibroblasts were isolated as described (Tumelty et al., 2014) from 
C57Bl/6 mice harboring SMA-Chry and Col-Tpz reporter transgenes (provided by Dr. 
David Rowe) (Bilic-Curcic et al., 2005). Mice were euthanized with carbon dioxide and 
the lungs were removed. The lungs were minced and then digested with 1x dispase 
(Worthington), 1 mg/ml type 1 filtered collagenase (Fisher) and 0.0045 mg/ml DNase 
(Worthington). Primary lung fibroblasts were cultured in DMEM containing 10% FBS. 
The Boston University School of Medicine Institutional Animal Care and Use Committee 
(IACUC) approved all animal experiments.  
 
Softwell Plate Procedure 
Plates were coated before cells were plated with recombinant ACLP (1.5 µg) or 
with recombinant discoidin (1.5 µg). To coat the plates, recombinant ACLP and discoidin 
proteins were diluted in Dulbecco’s phosphate-buffered saline (DPBS) (Corning) and 
then added to the wells and incubated overnight at 37°C and 5% CO2. The recombinant 
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ACLP used was a full-length mouse ACLP (Tumelty et al., 2014). The recombinant 
discoidin domain used was the central collagen binding discoidin domain that was 
expressed in 293 cells and similar to the protein described by Schissel et al 2014. 
Fibroblasts (250,000 cells/6 well) were plated on 50 kPa collagen I coated Softwell plates 
(Matrigen) with the additional ACLP proteins as described above. After three days 
proteins were harvested and analyzed using Western Blot analysis.  
 
Protein Extraction and Western Blot Analysis 
For IMR90 cells, proteins were extracted using a protein extraction buffer 
consisting of 25 mM Tris pH 7.4, 50 mM sodium chloride, 0.5 % sodium deoxycholate, 
2% NP-40, and 0.2% SDS. This buffer also contained protease and phosphatase 
inhibitors (Roche).  
For Softwell plate experiments, proteins were extracted by incubating wells at 
37°C and 5% CO2 with 0.25% trypsin-EDTA (Corning) for 5 minutes. DMEM with 10% 
FBS was then added to neutralize the trypsin and then samples were spun down at 250x g 
at 4°C for 5 minutes. Cells were then washed with cold PBS and spun down using the 
same conditions. Protein extraction buffer was then added as described above.  
The BCA microplate assay (Pierce) was conducted to determine protein 
concentrations using a standard curve containing BSA. Samples were diluted so that 
concentration was the same for each sample and 5x-loading buffer (0.25% bromophenol 
blue, 0.5 M DTT, 50% glycerol, 10% SDS, 0.25 M Tris) was added. The samples were 
heated at 99°C for 4 minutes and run on 4-20% Mini-Protean TGX Gels (Bio-Rad). The 
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gels were transferred onto a nitrocellulose membrane (GE Healthcare) using transfer 
buffer containing 48 mM Tris pH 8.3, 39 mM glycine, 0.037% SDS, and 20% methanol. 
The transfer was carried out at 23 volts overnight in a 4°C room. Blots were then 
equilibrated in TBST buffer containing 25 mM Tris pH 8.0, 125 mM sodium chloride, 
and 0.1% Tween 20. Next, the blots were blocked for 35 minutes at room temperature in 
5% milk in TBST. When using the phospho-Smad3 antibody the blots were blocked in 
3% bovine serum albumin-TBST. The antibodies used were phospho-Smad3 (Cell 
Signaling Cat # 9520, 1:1000), total Smad2/3 (Cell Signaling, Cat# 8685, 1:1000), ACLP 
(Layne et al., 1998)(1:1000), α-smooth muscle actin (Sigma, Cat# A2547 1:1000), 
collagen α1 (I) (Rockland, Cat # 600401 D19, 1:1000), and GAPDH (Santa Cruz 
Biotechnology, Cat# sc32233, 1:1000). Antibodies were diluted in blocking buffer and 
incubated over night at 4°C. The ACLP antibody was incubated at room temp for 2 
hours. After the primary antibody was added the membranes were washed 3 times in 
blocking buffer and then the secondary antibody was added, which was either anti-rabbit 
IgG horseradish peroxidase (HRP) or anti-mouse IgG-HRP (GE Healthcare 1:4000). 
Blots were incubated with the secondary antibody for 1 hour at room temp and then 
washed 3 times in TBST. SuperSignal West Dura Extended Duration Substrate (Pierce) 
was added to the membrane in a ratio of 1:1 and imaged using a Bio-Rad Chemidoc 
system.  
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Collagen Polymerization Assays 
A polymerization assay was used to determine the effects of ACLP on collagen 
polymerization (Damodarasamy et al., 2010). The absorption readings in this assay 
measured the polymerization of collagen into fibrils over time (Damodarasamy et al., 
2010). Rat tail type I collagen (BD Bioscience) was used to create solutions, which 
consisted of collagen at a concentration of 0.06 mg/ml in 1x PBS. Additionally, 
recombinant ACLP was added to the solution (0.02 mg/ml or 0.002 mg/ml). A solution of 
collagen in 1x PBS was used as a control. A program was set up in the plate reader 
software Gen5 (BioTek) that measured absorbance of the samples every thirty seconds 
for one hour at a wavelength of 410 nm at 37°C. Data were plotted and maximum 
absorbance as well as time lag were compared among the samples (Tumelty, 2014).  
 
DNA Extraction 
For genomic DNA extraction from mouse tails a solution was made using 
DirectPCR Lysis Reagent (Viagen) with proteinase K (0.1 μg/ml) (Roche). Samples were 
placed in a heat block at 55°C overnight. The samples were then heated at 85°C for 40 
minutes. The samples were spun down for two minutes at 4°C at 12,000 x g and the 
supernatant was retained for PCR (below). 
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Genotyping  
  A PCR reaction mixture was set up, which included 5x Crimson Taq reaction 
buffer deoxynucleotide solution mix, water, Crimson Taq DNA Polymerase (New 
England BioLabs) and primers, which included either lox Forward and Reverse 
(Invitrogen) or cre Forward and Reverse (Invitrogen) (Table 1). Two different PCR 
conditions were used for the different sets of primers (Tables 2 and 3). Gel 
electrophoresis was carried out on the PCR samples with 2% agarose gels and run in 1 x 
tris acetate-EDTA (TAE) buffer to determine genotype of samples. The gel was imaged 
using the Gel Doc XR program (Bio-Rad).  
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Table 1. Primer sequences. 
 
 
 
Primer Name Nucleotide Sequence 
1. Aebp1-loxF 5’GGAGATCTGATACTGCAAAGAGAAAGG3’ 
2. Aebp1-loxR 5’GCAGAGCTCCTGAGAGAACAGTGG3’ 
3. Aebp1-flxF 5’CTCTAAGTCTCTTGGCCCTGTTACC3’ 
4. Aebp1-flxR 5’TTGACTGATAGTGACCTGTTCGTTGC3’ 
5. Aebp1-creF 5’GCGGTCTGGCAGTAAAAATATC3’ 
6. Aebp1-creR 5’GTGAAACAGCATTGCTGTACTT3’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Cre PCR conditions. 
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Steps  Temp (°C) Time (m:ss) # of Cycles 
1.Denaturation 95 5:00 1 
2.Denaturation 95 0:15 X10 
3. Annealing  65 0:15 
4. Extension  68 0:30 
5.Denaturation 95 0:15 X25 
6. Annealing  52 0:30 
7. Extension 68 0:30 
8.Final 
Extension 
68 1:00 1 
9. Finish  4 Hold  
 
 
 
 
Table 3. Lox PCR conditions. 
 
Steps  Temp (°C) Time (m:ss) # of Cycles 
1.Denaturation 94 5:00 1 
2.Denaturation 94 0:15 X10 
3. Annealing  65 0:30 
4. Extension  72 0:40 
5.Denaturation 94 0:15 X25 
6. Annealing  55 0:30 
7. Extension 72 0:40 
8.Final 
Extension 
72 1:00 1 
9. Finish 4 Hold  
 
  
 19 
CHAPTER 3 
ROLE OF ACLP ON STIFF MATRICES AND IMPACT ON COLLAGEN 
POLYMERIZATION 
 
Recent work in our laboratory has focused on the profibrotic mechanism of ACLP 
(Schissel et al., 2009, Tumelty et al., 2014). ACLP is a secreted ECM protein that is 
highly expressed in fibrotic lungs and activates the Smad signaling pathway (Tumelty et 
al., 2014). Furthermore, there has been work on the effect of matrix stiffness and 
mechanical signaling pathways on the actions of ACLP and the development of fibrosis. 
Previous research in this laboratory and others have shown that stiffer surfaces promote 
fibroblast differentiation. The goal of these studies was to examine the relationship 
among mechanical signaling pathways, matrix stiffness and ACLP action. It was 
hypothesized that the combination of collagen I and ACLP on a stiff matrix would cause 
an increase in myofibroblast differentiation.   
 To investigate the role of mechanical signaling pathways and matrix stiffness on 
ACLP action, primary lung fibroblasts were plated on plates of a defined stiffness and 
their differentiation into myofibroblasts was examined. Also, we investigated if the 
central collagen-binding domain of ACLP (discoidin domain) was sufficient to mediate 
these effects. An additional goal of these studies was to examine the impact of ACLP on 
the mechanical properties of polymerized collagen.  
 
ACLP Treatment Leads to Phosphorylation of Smad3  
Initial experiments were performed to replicate the observation that ACLP 
promotes IMR90 myofibroblast differentiation (Tumelty et al., 2014). IMR90 cells were 
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treated with ACLP or TGFβ (1 nM) for 30 minutes and then proteins were harvested and 
analyzed by Western Blot analysis. As anticipated, both ACLP and TGFβ treated cells 
exhibited elevated phosphorylated Smad3 levels (Figure 1). These studies provided the 
foundation for combining ACLP with matrices of defined surfaces. 
 
ACLP Increases Expression of Myofibroblast Markers 
To examine the role of ACLP and in particular the collagen binding discoidin 
domain of ACLP on fibroblast to myofibroblast differentiation and mechanical signaling, 
mouse primary lung fibroblasts were grown on a 50 kPa softwell 6 well plates that were 
coated with recombinant ACLP (1.5 μg) or with recombinant discoidin (1.5 μg). These 
proteins were combined with collagen I. Primary lung fibroblasts were plated on a plastic 
surface immediately after isolation and then were plated onto the collagen coated plates 
24 hours afterwards. After 3 days proteins were extracted and analyzed by Western blot 
analysis (Figure 2). Cells that were grown on the wells coated with ACLP and collagen 
exhibited greater expression of myofibroblast markers (SMA and collagen) when 
compared to the control wells, which only contained a collagen coating. In these 
experiments, the addition of discoidin to the collagen well did not result in noticeable 
differences from the control (collagen only).  
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ACLP Potentiates the Effects of TGFβ on Fibroblasts 
It has been shown previously that ACLP has an additive or cooperative effect 
with TGFβ (Tumelty et al., 2014). The next goal was to examine the relationship of 
ACLP with TGFβ on a stiff matrix. An additional goal was to examine whether the 
discoidin domain would increase myofibroblast markers on a stiff matrix. It was 
hypothesized that discoidin, through its interaction with the collagen matrix might 
potentiate the effects of TGFβ. An example of this is seen with the protein osteopontin. 
Osteopontin is believed to interact with both fibroblasts and collagen, which cause matrix 
contraction (Ashizawa et al., 1996). To examine the function of ACLP and the discoidin 
domain, primary lung fibroblasts were isolated and plated on plastic. ACLP and discoidin 
were coated on 50 kPa 6 well plates, which already contained a collagen coating. After 
24 hours the cells were plated onto the softwell plates either in medium containing TGFβ 
(1 nM) or only medium. Proteins were extracted after 3 days. In the absence of 
exogenous TGFβ, consistent with the previous results (Figure 2), ACLP coating resulted 
in increased expression of SMA. ACLP and TGFβ together also increased the expression 
of SMA, however, discoidin coated wells with exogenous TGFβ did not result in elevated 
myofibroblast differentiation when compared to control wells (Figure 3). 
 
ACLP Increases the Overall Polymerization of Collagen I 
It is known that the discoidin domain of ACLP binds to collagen and this may 
have an effect on its polymerization (Tumelty and Layne, unpublished). To examine the 
effects of ACLP on collagen polymerization, solutions of collagen were mixed with 
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different doses of ACLP and the absorbance at 410 nm was measured over time. Upon 
addition of ACLP to the solution, the polymerization was delayed and extent of the delay 
was dependent on the concentration of ACLP (Figure 4). Additionally, there was 
increased polymerization observed in the solutions containing ACLP compared to the 
collagen only solution (Figure 4). The amount of polymerization was also dependent on 
the concentration of ACLP in the solution as the higher dose displayed a greater amount 
of polymerization (Figure 4). The collagen solution with the high dose of ACLP shows 
the longest time lag until polymerization and also shows the highest absorbance at 410 
nm.  
 
SUMMARY OF RESULTS 
The goal of these studies was to determine if the discoidin domain of ACLP on a 
stiff matrix with coated collagen would have an influence on myofibroblast 
differentiation. The induction of phosphorylated Smad3 by ACLP was replicated. ACLP 
was shown to increase the expression of myofibroblast markers while discoidin did not 
appear to have the same effect. ACLP also had an additive effect with TGFβ by 
increasing the expression of myofibroblast markers, while this additive effect was not 
observed with discoidin and TGFβ. Lastly, ACLP increased the overall polymerization of 
collagen I and also increases the time lag of polymerization.  
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Figure 4. ACLP increases lag time as well as overall polymerization of collagen 
fibrils. The turbidity of solutions containing collagen (0.6 mg/ml) with or without 
different concentrations of ACLP was measured. A high or low dose of ACLP was given 
(20 μg/ml or 2 μg/ml). The solutions were read at 410 nm for 1 hour.  
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CHAPTER 4 
GENERATION AND GENOTYPING OF ACLP-FLOXED MICE 
 
The goal of this work is to develop a conditional deletion of the ACLP gene to 
test whether the deletion of ACLP after the initiation of fibrosis will slow or even stop the 
fibrotic process. A floxed ACLP allele (ACLPflx) was previously generated in the 
laboratory by inserting a loxP site upstream of the promoter and a second loxP site 
between exons 6 and 7 (Figure 5). This mouse was created using a targeting construct 
designed in consultation with the Mouse Biology Program at University of California 
Davis. A tamoxifen-inducible cre line was then utilized (Jackson Laboratory, B6.Cg-Tg 
(CAG-cre/Esr1*) 5Amc/J). These mice were then bred to ACLPflx mice by Dahai Wang 
in the Layne laboratory. The goal of this study was to optimize genotyping conditions for 
these ACLPflx mice. A second goal was to develop assays to detect the Cre mediated 
recombination event using and analyze the efficacy of tamoxifen treatment to 
conditionally delete ACLP  
 
Optimization of PCR Conditions Allowed for Detection of Floxed Genotype  
To optimize genotyping procedures several variables were considered including 
primer annealing temperatures and times, enzyme extension temperature, and 
denaturation temperature. In order to amplify the DNA by PCR, the DNA needs to be 
denatured into single strands, which is the purpose of the denaturation step (Walsh et al., 
1992). Primers then associate with the single strands in the annealing step and after 
association of primers, the extension step occurs, which is where DNA polymerase adds 
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complementary sequences (Walsh et al., 1992). To determine the optimum annealing 
temperature a gradient was established in the PCR machine. The optimal temperature for 
annealing was 61°C because the bands for each temperature were strong, but it was 
important to keep the reaction as hot possible to increase specificity (Figure 6, lane 3). 
Denaturation temperature was also raised to 95°C from 94°C. Recognizing that the 
polymerase used in these studies (Crimson Taq DNA Polymerase) was optimal at 68°C 
and not the usual 72°C the extension temperature was set to 68°C. This new set of PCR 
conditions was then validated on DNA extracted from mice tails.  
To extract genomic DNA from mouse tail biopsies, tails were mixed with a 
solution of Direct PCR Lysis Reagent and the extracted DNA was used for PCR 
(described in Materials). With these optimized PCR conditions the bands for cre positive 
mice were robust, and of the expected size (Figure 6). The cre allele was detected using 
the creF and creR primers. Genotyping gave a band for cre at ~100 bp (Figure 7, lanes 1-
3). Mice that were homozygous for the floxed allele, wildtype, or heterozygous were 
distinguished using the loxF and loxR primers. The DNA of mice that were homozygous 
for the floxed allele contained a band at 324 bp while the mice that were wildtype 
contained a band at 290 bp (Figure 7, lanes 1-3). Heterozygous mice had a band in each 
position (Figure 7, lane 4). Through the utilization of the optimized genotyping 
conditions, homozygous flx cre positive mice were identified and then used for the 
second part of the study. 
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Figure 5. Model of ACLP gene. The wildtype mice contained no lox p 
sites.  Mice with the floxed allele contained two lox p sites and a frt 
insertion.  Recombinant mice contained a deletion between the lox p 
sites. Adipocyte enhancer binding protein I (AEBP-I) is the mouse 
version of ACLP.   
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Genotyping Determined Recombination Following Tamoxifen Treatment  
The next step was to conditionally delete the ACLP gene with the tamoxifen 
controlled cre. Mice expressing the tamoxifen controlled cre allele (CreEr) that were 
homozygous for the flx ACLP allele were treated with tamoxifen (experiments performed 
by Dahai Wang). Tamoxifen acts as an estrogen receptor ligand and activated cre 
recombinase, which then excises the DNA between the loxP sites (Feil et al., 2009). 
Tissues from control and tamoxifen treated mice were extracted for DNA, RNA, protein 
and histological analysis. The DNA was extracted from the lungs and livers of the mice. 
After genotyping with the primers loxF and flpR, recombination was observed in the two 
mice treated with tamoxifen. Cre-mediated recombination was detected by the 
appearance of a 238 bp band (Figure 8, lanes 3-6). As expected, the absence of bands in 
the control mouse showed that there was no recombination (Figure 8, lanes 1 and 2).  
 
Efficacy of Tamoxifen-Mediated Recombination 
In order to test the efficacy of the tamoxifen treatment, a mouse that displayed 
recombination were genotyped using the loxF and loxR primers and creF and creR 
primers to confirm that they were homozygous for the floxed allele and also cre positive. 
A control mouse did not show recombination was also genotyped. The tamoxifen 
treatment was efficient, as the recombinant mouse contained the floxed allele and was cre 
positive (Figure 9, lanes 1 and 2).  Additionally, the control mouse contained the floxed 
allele, but was not cre positive, meaning that tamoxifen treatment would not lead to 
recombination (Figure 9, lanes 3 and 4).     
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SUMMARY OF RESULTS 
The goal of this work was to optimize genotyping conditions for ACLPflx mice 
and establish genotyping conditions to detect tamoxifen inducible cre-mediated 
recombination. The optimized PCR conditions provided an efficient way to determine 
which mice were homozygous for the floxed allele and also cre positive. Genotyping 
using the loxF and flpR primers allowed the detection of cre recombination. Lastly, 
through genotyping the DNA of the recombined mice the tamoxifen treatment was 
efficient in causing recombination. Current studies are examining the efficacy of cre 
mediated ACLP deletion by examining RNA by quantitative PCR and protein by Western 
blot and immunohistochemistry.  
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CHAPTER 5 
DISCUSSION 
 
 Fibrosis is often described as uncoordinated wound healing and results in 
excessive ECM deposition, scarring and tissue dysfunction (Darby & Hewitson, 2007). 
Current research has identified TGFβ and mechanical signaling as key pathways in the 
progression of IPF. However, there has been no molecular target that has been effective 
in the treatment of IPF.  
In this study,  the effects of altering the matrix stiffness and ACLP on TGFβ 
signaling were examined. Additionally, genotyping conditions were optimized to allow 
detection of mice with the floxed ACLP allele and also to detect recombination due to cre 
recombinase activity. It was hypothesized that the combination of ACLP and collagen I 
on a matrix stiffer than a physiological matrix would increase myofibroblast markers.  
 
ACLP Induces Phosphorylation of Smad3 
This investigation centered around the protein ACLP and its influence on the 
progression of fibrosis. ACLP is a secreted protein that is expressed in the vasculature, 
lung, and skin of adult organisms and its expression is increased during tissue injury 
(Layne et al., 2001). Additionally, developmental expression of ACLP was found in 
collagen rich tissues, which further argued that it had a regulatory or structural role (Ith et 
al., 2005). Studies on ACLP also showed that ACLP was downregulated during 
adipocyte differentiation and increased expression of ACLP increased expression of 
SMA while stopping this differentiation (Abderrahim-Ferkoune et al., 2004). This 
induction of SMA was also found in our laboratory when IMR90s were treated with 
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ACLP (Tumelty et al., 2014). This finding provided a mechanistic basis for the 
involvement of ACLP in lung fibrosis because mice without ACLP exhibit decreased 
collagen deposition and fewer myofibroblasts and were protected against lung fibrosis 
(Schissel et al., 2009).  
Our laboratory’s recent work demonstrated that ACLP binds to TGFβ type II 
receptor, which then leads to Smad3 phosphorylation and induction of SMA (Tumelty et 
al., 2014). Recent work has shown that physiological soft matrices reduce fibroblast 
contractile abilities due to Smad3 activation (Marinković, et al., 2012).  This led to 
speculation that soft matrices may decrease TGFβ activity (Marinković et al., 2012). The 
work presented here show that stiff matrices increased the effects of ACLP and that 
matrix stiffness affects ACLP action and TGFβ signaling. Stiffer matrices may lead to 
Smad2/3 activation and translocation by ACLP, while physiologic matrices may stop 
Smad2/3 activation through mechanical signaling.    
 
Matrix Stiffness and Mechanical Signaling  
 Previous work in this laboratory demonstrated that stiffer matrices increased 
ACLP expression and myofibroblast differentiation (Tumelty, 2014). Additionally, it is 
known that matrix stiffening induces ROCK activity and leads to the continuation of the 
fibrotic process (Huang et al., 2012). In order to gain a further understanding of how 
ACLP and mechanical signaling relate, we explored the effects of ACLP on stiff 
matrices.  
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Mechanical stiffness affects the actions of TGFβ, as it was shown that TGFβ 
induction of SMA was dependent on the resistance of the matrix (Arora et al., 1999). 
Also, when rat kidney mesangial cells were stretched, expression of TGFβ isoforms was 
increased (Riser et al., 1996). Furthermore, research has shown that latent TGFβ is 
activated by myofibroblasts and as the stiffness increases, more latent TGFβ is activated 
(Wipff et al., 2007). Since ACLP is known to increase fibroblast to myofibroblast 
differentiation and was shown to precede SMA expression, it is possible that ACLP 
contributes latent TGFβ activation (Tumelty et al., 2014). These studies may further link 
ACLP and TGFβ action with matrix stiffness.  
 The findings that matrix stiffness increases ACLP action may be linked through 
the Rho/ROCK pathway of mechanotransduction. This pathway is considered a target for 
treatment of lung fibrosis. The Rho kinase inhibitor fasudil reduced lung fibrosis in mice 
treated with bleomycin (Jiang et al., 2012). Furthermore, fasudil inhibition led to a 
reduced amount of TGFβ and SMA production (Jiang et al., 2012). Protective effects of 
fasudil were also seen in other studies where fasudil prevented myofibroblast 
differentiation and also directly targeted myofibroblasts for apoptosis (Zhou et al., 2013). 
Lastly, pulmonary hypertension often occurs secondary to pulmonary fibrosis (Bei et al., 
2013). Long term treatment of bleomycin induced fibrotic and pulmonary hypertensive 
mice with fasudil showed protective effects against the fibrosis and hypertension (Bei et 
al., 2013). This effect was partly through inhibition of Smad2/3 phosphorylation in TGFβ 
signaling (Bei et al., 2013).       
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   Inhibition of the ROCK pathway not only affects myofibroblast formation, but it 
also changes gene expression within the myofibroblasts (Thannickal et al., 2014). This 
altered gene expression pattern provides a connection of the ROCK pathway to 
myocardin-related transcription factor A (MRTFA), which is a transcriptional activator 
involved in the regulation of SMA and collagen (Small et al., 2010, Luchsinger et al., 
2011). MRTFA knockout mice displayed reduced cardiac fibrosis following a myocardial 
infarction (MI) (Small et al., 2010). Additionally, kidney epithelial cells showed 
increased MRTFA activity in response to TGFβ signaling (Elberg et al., 2008). As a 
result, MRTFA is believed to play a role in TGFβ signaling and ROCK signaling during 
fibrosis. It was also shown that ROCK pathway inhibition reduces induction of MRTFA 
(Small et al., 2010). Lastly, inhibition of nuclear accumulation of MRTFA in lung 
fibroblasts prevented myofibroblast differentiation and fibrosis in mice (Sisson et al., 
2014.). These studies link MRTFA with TGFβ signaling and ROCK signaling in the 
progression of fibrosis. Interestingly, however, work in this lab demonstrated that ACLP 
regulated collagen independent of MRTFA as ACLP knockdown did not result in a 
significant reduction in collagen (Tumelty et al., 2014). Therefore, on a stiff matrix, the 
ROCK pathway increases collagen through MRTFA, while ACLP upregulates collagen 
deposition through a different mechanism, both leading to a feed forward mechanism of 
continuous collagen deposition. ACLP may do this by through direct interaction with 
collagen.     
Along with the ROCK pathway, recent research on IPF and the progress of 
fibrosis has implicated the transcription coactivator yes-associated protein (YAP) and the 
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transcriptional coactivator with PDZ-binding motif (TAZ) in regulation of fibroblasts and 
matrix synthesis due to matrix stiffness (Liu et al., 2015). YAP and TAZ knockdown 
decreased fibrotic matrix synthesis, contraction, and proliferation (Liu et al., 2015). 
Furthermore, this knockdown had a more profound effect on stiffer matrices compared to 
matrices of physiological stiffness (Liu et al., 2015). These studies connect matrix 
stiffness to the fibrotic process and it would be interesting to determine if ACLP and the 
YAP/TAZ pathway are related in fibrosis.    
 
ACLP Influences Collagen Polymerization  
Previous work in our laboratory demonstrated that ACLP altered the 
polymerization of collagen (Tumelty, 2014). We set out to repeat this finding and also 
analyze the mechanical properties of the polymerized collagen. This same effect was seen 
as the collagen solution that contained ACLP showed greater polymerization and also a 
time lag (Figure 4). To measure the mechanical properties of the polymerized collagen 
solutions we attempted to use atomic force microscopy (AFM) in collaboration with the 
Wong laboratory at Boston University. However, the collagen solutions created for the 
polymerization experiment were not firm enough for AFM to measure mechanical 
properties.  
ACLP may play roles similar to other collagen binding proteins. One example is 
periostin, which is protein that binds to matrix proteins such as collagen (Kii et al., 2006). 
In cardiac fibrosis following an myocardial infarction, periostin stabilized collagen cross 
linking (Naik et al., 2012). Furthermore, in periostin knockout mice, collagen fibrils had a 
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reduced diameter when compared to collagen fibrils of wildtype mice (Norris et al., 
2007). Periostin has also been linked in lung fibrosis as it is upregulated in fibroblasts 
from IPF patients (Naik et al., 2012). Collagen I expression in lung mesenchymal cells 
was increased by recombinant periostin and this finding leads to speculation that periostin 
may cross link collagen in the lungs and stiffen the matrix, which ultimately continues 
the process of fibrosis (Naik et al., 2012).      
   
IMPLICATIONS/FUTURE DIRECTIONS 
 These studies have shown that ACLP induction of SMA through Smad signaling 
is increased on stiff matrices. The ROCK pathways and ACLP may be involved in 
increasing matrix protein deposition and also myofibroblast differentiation. It is 
important to further understand the relationship between the two so that new therapies 
can be created based on this knowledge to slow or stop the progression of fibrosis. 
Additionally, in generating a novel mouse model where mice that are homozygous for the 
ACLP floxed allele and cre positive, cre recombination can lead to conditional deletion of 
the ACLP gene. Further research is ongoing with these mice to examine the role of ACLP 
in fibrosis.  
 These findings identified that ACLP action was increased on stiff matrices. It is 
possible that ACLP and mechanical signaling are connected through YAP/TAZ because 
YAP/TAZ are required for Smad activation and are seen in ROCK signaling (Varelas et 
al., 2008). It is postulated that ACLP may increase the stiffness of the matrix, which in 
return increases the effects of the ROCK pathway. It would be interesting to carry out 
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experiments with ACLP and a ROCK inhibitor to see how that influences the expression 
of myofibroblasts markers and help further understand how ACLP and the ROCK 
signaling pathway are related. A ROCK inhibitor may reduce the effects of ACLP, which 
would further show the relationship between the two.  
Furthermore, with the new mouse model, the ability to conditionally delete the 
ACLP gene will provide the opportunity to delete the gene after mice have been treated 
with bleomycin. By observing how fibrosis progresses after this deletion or if slows or 
stops all together will be very important in further understanding ACLP and fibrosis. 
Previous mouse models have knocked out various targets such as ACLP, periostin, 
MRTFA, and Smad3 (Schissel et al., 2009, Tumelty et al., 2014, Zhao et al., 2002). 
These knockouts were not conditional however, and therefore mice did not contain these 
genes before bleomycin induced fibrosis. With this new mouse model, ACLP can be 
deleted with tamoxifen treatment after the bleomycin-induced fibrosis. After the 
recombination, expression of myofibroblast markers can be analyzed to determine the 
effect of the deletion.  
 
CONCLUSIONS 
 The work in this study built upon previous studies in this laboratory that 
demonstrated the significance of ACLP in the progression of the fibrotic process. 
Additionally, it supported previous findings on the role of matrix stiffness and 
mechanical signaling in fibrosis. ACLP increased the expression of myofibroblast 
markers on stiff matrices. Furthermore, ACLP potentiated the effects of TGFβ on stiffer 
 43 
matrices. Lastly, through the optimization of genotyping procedures we were able to 
determine mice that contained the floxed allele and detect recombination following 
tamoxifen treatment. Future work will investigate the effect of conditionally deleting the 
ACLP gene and the relationship between mechanical signaling and ACLP action. 
Research in these areas can possibly provide targets and strategies for treating IPF.   
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